Alzheimer’s Clinical Trials Face Global Participant Shortage
According to Alzheimer’s Disease International, clinical trials for Alzheimer’s disease treatments face a global shortage of participants, risking slowing progress in dementia therapies. To sustain active clinical pipelines amid high screening rejection rates, an estimated 350,000 applicants are needed worldwide. Global Alzheimer’s Clinical Trials Pipeline and Participant Shortfall The global federation of Alzheimer associations released … Read more